Structure-based development of novel substrate-type G9a inhibitors as epigenetic modulators for sickle cell disease treatment.
Nishigaya Y, Takase S, Sumiya T, Sato T, Niwa H, Sato S, Nakata A, Matsuoka S, Maemoto Y, Hashimoto N, Namie R, Honma T, Umehara T, Shirouzu M, Koyama H, Yoshida M, Ito A, Shirai F.
Nishigaya Y, et al. Among authors: yoshida m.
Bioorg Med Chem Lett. 2024 Sep 15;110:129856. doi: 10.1016/j.bmcl.2024.129856. Epub 2024 Jun 22.
Bioorg Med Chem Lett. 2024.
PMID: 38914346